CHINET 2014 surveillance of bacterial resistance in China

Chinese Journal of Infection and Chemotherapy

Volumn 15, Issue 5, 2015, Pages 401-410

  Hu, Fupin ^a   Zhu, Demei ^a   Wang, Fu ^a   Jiang, Xiaofei ^a   Xu, Yingchun ^a   Zhang, Xiaojiang ^a   Zhang, Zhaoxia ^a   Ji, Ping ^a   Xie, Yi ^a   Kang, Mei ^a   Wang, Chuanqing ^a   Wang, Aimin ^a   Xu, Yuanhong ^a   Shen, Jilu ^a   Sun, Ziyong ^a   Chen, Zhongju ^a   Ni, Yuxing ^a   Sun, Jingyong ^a   Chu, Yunzhuo ^a   Tian, Sufei ^a   Hu, Zhidong ^a   Li, Jin ^a   Yu, Yunsong ^a   Lin, Jie ^a   Shan, Bin ^a   Du, Yan ^a   Han, Yanqiu ^a   Guo, Sufang ^a   Wei, Lianhua ^a   Wu, Ling ^a   Zhang, Hong ^a   Kong, Jing ^a   Hu, Yunjian ^a   Ai, Xiaoman ^a   Zhuo, Chao ^a   Su, Danhong ^a   more..

^a FUDAN UNIVERSITY   (China)

Author keywords

Antimicrobial susceptibility testing; Bacterial resistance surveillance; Carbapenemase; Extensively drug resistant bacillus; Methicillin resistant staphylococcus; Multi drug resistant bacterium; Penicillin resistant streptococcus pneumoniae; Vancomycin resistant enterococcus

Indexed keywords

BETA LACTAM; CARBAPENEM; COTRIMAZINE; IMIPENEM; RIFAMPICIN; VANCOMYCIN;

ACINETOBACTER; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE SURVEILLANCE; ENTEROBACTERIACEAE; ENTEROCOCCUS; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS; STREPTOCOCCUS PNEUMONIAE;

EID: 84979252962     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MMDR) among Gram-negative bacilli: need for international harmonization in terminology [J]. Clin Infect Dis, 2008, 46(7) 1121-1122.
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testingCS]. Twenty-fourth informational supplement, 2014, M100-S24.
3. Hu F, Chen S, Xu X, et al. Emergence of carbapenem-resistant Enlerobacleriaceae clinical isolates from a teaching hospital in Shanghai, China[J]. J Med Microbiol, 2012, 61 (Pt 1): 132-136.
4. Van Duin D, Kaye KS, Neuner EA, et al Carbapenem-resistant Enlerobacleriaceae: a review of treatment and outcomes [J]. Diagn Microbiol Infect Dis, 2013, 75(2): 115-120.
5. Daikos GL, Tsaouci S, Tzouvelekis LS, et al Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems[J]. Antimicrob Agents Chemother, 2014, 58(4): 2322-2328.
6. Tascini C, Jagliaferri E, Giani T, et al. Synergistic activity of colistin plus rifampin againtt colistin-resistant KPC-producing Klebsiella pneumoniae [J]. Antimicrob Agents Chemother, 2013, 57 (8): 3990-3993.
7. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enlerobacleriaceae-. an evolving crisis of globll dimensions [J]. ClinMicrobiolRev, 2012, 25(4)-682-707.